For pre-sleep pulsatile GH protocols, use without DAC (Mod GRF 1-29). For sustained GH elevation studies, use with DAC. Most protocols pair without-DAC with Ipamorelin for the most natural GH pulse pattern, achieving 4–8× GH amplification over baseline with minimal side-effect profile.
What is the Drug Affinity Complex?
DAC stands for Drug Affinity Complex — a lysine-maleimide linker chemically bonded to the CJC-1295 peptide chain. This molecular addition fundamentally changes how the compound behaves in the bloodstream.
When injected, the maleimide group covalently binds to the cysteine-34 residue on circulating serum albumin — the most abundant protein in blood plasma. This albumin-binding mechanism shields the peptide from enzymatic degradation and renal clearance.
The result: a half-life extension from approximately 30 minutes to 6–8 days. The same GHRH analog that would otherwise be cleared in less than an hour becomes a week-long GH secretagogue.
CJC-1295 + DAC injected subcutaneously
Maleimide group in DAC linker encounters serum albumin
Covalent bond forms with Cys-34 on albumin molecule
Albumin-peptide complex circulates with albumin half-life (~19 days)
Peptide slowly releases and activates pituitary GHRH receptors over 6–8 days
With DAC vs. Without DAC — Full Comparison
| Feature | With DAC | Without DAC (Mod GRF 1-29) |
|---|---|---|
| Half-life | 6–8 days | 29–30 minutes |
| GH release pattern | Sustained elevation | Sharp pulsatile |
| Dosing frequency | 1–2× per week | 1–3× daily |
| Pair with Ipamorelin | Not typically | Yes — optimal combination |
| Mimics natural GH secretion | No | Yes |
| Ideal for | Sustained elevation studies | Pulsatile GH studies |
Half-Life Deep Dive
- Albumin-binding mechanism extends circulation dramatically
- Produces a blunted but sustained elevation in GH levels across the week
- IGF-1 levels remain measurably elevated for up to 2 weeks post-injection
- Reduced injection burden — 1 to 2 injections per week maintains coverage
- Consideration: chronic elevation may downregulate somatotroph sensitivity over time — receptor desensitization is a documented concern with prolonged use
- Rapid clearance produces a sharp, physiological GH peak matching natural GHRH pulse patterns
- GH peaks within 15–30 minutes of injection — mirrors the body's own pulsatile secretion rhythm
- Maintains pituitary sensitivity through natural on/off cycling
- Synergistic pairing: Ipamorelin (GHSR agonist) amplifies the GH pulse 4–8× above the response of either peptide alone
- Pre-sleep administration aligns with the largest natural nocturnal GH pulse for maximum anabolic signaling
Dosing Protocols
Which Should You Choose?
The correct form depends entirely on the research objective. Three common scenarios and the optimal approach for each:
Pair 100mcg Mod GRF 1-29 with 200mcg Ipamorelin pre-sleep. This delivers a sharp, synchronized GH pulse that mirrors physiological secretion during slow-wave sleep — the most anabolically favorable window.
CJC-1295 with DAC maintains elevated IGF-1 levels throughout the week with once or twice weekly injections. Useful for research models requiring consistently elevated GH without frequent administration.
Use Mod GRF 1-29 / Ipamorelin as the daily pulsatile driver, and layer in low-dose CJC-1295 DAC (0.5–1mg) once every 1–2 weeks as a sustained baseline amplifier. Advanced research protocol.
CJC-1295 / Ipamorelin Stack
The without-DAC pairing is the most studied GH secretagogue combination in research literature. CJC-1295 (Mod GRF 1-29) provides the GHRH signal while Ipamorelin provides the ghrelin-mimetic pulse — together they activate both GH secretagogue pathways simultaneously for synergistic 4–8× GH amplification with minimal interference with cortisol or prolactin.